GlassScriptPhysician profile
Ken W Chow
NPI 1699781203
$23,834.39
in general payments reported to CMS, 2019-2025
39 companies · $4,833 in 2025
The $4,833 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,518 · 2020: $2,129 · 2021: $3,481 · 2022: $3,327 · 2023: $3,403 · 2024: $4,143 · 2025: $4,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,365.46 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,825.77 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,308.10 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $2,306.45 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $2,199.67 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $1,074.40 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $912.79 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $789.70 | 2019-2024 | Dificid |
| Lilly USA, LLC | $670.23 | 2023-2025 | Omvoh |
| Pfizer INC. | $576.83 | 2019-2024 | |
| Madrigal Pharmaceuticals | $544.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $448.19 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $431.10 | 2020-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $391.84 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $381.18 | 2019-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $351.68 | 2021-2024 | Injectafer |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $345.60 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $341.52 | 2024-2025 | Vowst, Zenpep |
| Organon LLC | $339.50 | 2021-2025 | Renflexis, Hadlima |
| Ardelyx, INC. | $322.60 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $319.68 | 2025 | Iqirvo |
| Allergan, INC. | $302.62 | 2019-2020 | |
| Braintree Laboratories, INC. | $271.33 | 2019-2025 | Sutab, Suflave |
| Shire North American Group INC | $200.00 | 2019 | |
| Intercept Pharmaceuticals, INC. | $194.92 | 2020-2025 | Ocaliva |
| Celgene Corporation | $186.11 | 2021-2024 | Zeposia |
| Capsovision, INC. | $138.68 | 2023-2025 | Capsocam Plus |
| Alnylam Pharmaceuticals INC. | $94.81 | 2021-2024 | Givlaari |
| Exact Sciences Corporation | $84.28 | 2023 | Cologuard Collection Kit |
| Echosens North America, INC. | $84.06 | 2023 | Fibroscan |
| Redhill Biopharma INC. | $80.61 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $75.63 | 2019-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $56.47 | 2025 | Voquezna |
| Alfasigma USA, INC. | $46.72 | 2020-2022 | |
| Shionogi INC | $38.04 | 2019 | |
| Amgen INC. | $34.54 | 2020-2021 | |
| Mauna Kea Technologies, INC. | $20.08 | 2019 | |
| Acacia Pharma INC | $17.07 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.10 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.